

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Jun 2026

Effect of Ferula assafoetida on clinical and paraclinical indices of polycystic ovarian syndrome and its comparison with LD tablet.

Protocol summary

Presence of ovarian cysts, occurrence of menstruation bleeding, hirsutism

Study aim

1- Effect of Ferula assafoetida on: 1-1- Improvement of menstrual status and hirsutism 1-2- Body mass index (BMI) and laboratory tests 1-3- Treatment of ovarian cysts in patients with Polycystic ovarian syndrome 2- It's comparison with Ld tablet.

Design

Two arm parallel group randomized clinical trial, double-blind, with 30 patients.

Settings and conduct

The study will be conducted in Mostafa Khomeini hospital in Tehran. Thirty patients with diagnosis of Polycystic ovarian syndrome will be selected and after doing different tests (CBC, LIPID PROFILE, FBS, AST, ALT, ALK.P, TOTAL TESTESTRONE, FREE TESTESTRONE), ovarian ultrasound, hirsutism examination and filling demographic information questionnaires, will enter the study. Patients meeting the inclusion and exclusion criteria randomly will divide into two groups, using a double-blind design. One group will be treated with Ferula Assafoetida capsules (1gram per day) and other group will be treated with OCP (0.03 mg Ethinyl Estradiol and 0.3 mg Norgestrel or 0.15 mg Levonorgestrel). Patients will be asked to use the drugs for three weeks and discontinue the consumption for one week. Thereafter, patients will use the drugs for an extra three weeks. Finally, they will be evaluated after seven to ten days.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 15 to 40 years old women with Polycystic ovarian syndrome. Exclusion criteria: Pregnancy, diabetes, thyroid diseases, allergy to Ferula Assafoetida, differential Diagnosis cases of PCOS

Intervention groups

Case group: Intervention with Ferula assafoetida capsule (1 gr per day) for 6 weeks. Control group: Intervention with ocp (LD tablet: 0.03 mg ethinyl estradiol and 0.3 mg norgestrel or 0.15 mg levonorgestrel) for 6 weeks.

Main outcome variables

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190728044360N1**

Registration date: **2019-12-11, 1398/09/20**

Registration timing: **registered_while_recruiting**

Last update: **2019-12-11, 1398/09/20**

Update count: **0**

Registration date

2019-12-11, 1398/09/20

Registrant information

Name

Najmeh Dehparvar

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 25 3770 1938

Email address

n.dehparvar@shahed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-12-11, 1398/09/20

Expected recruitment end date

2020-06-09, 1399/03/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of Ferula assafoetida on clinical and paraclinical indices of polycystic ovarian syndrome and its comparison with LD tablet.

Public title

Effect of Ferula Assafoetida on polycystic ovarian syndrome

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

All 15 to 40 years old women with polycystic ovarian syndrome

Exclusion criteria:

Pregnancy Allergy to Ferula Asafoetida Diabetic patients
Thyroid diseases

Age

From **15 years** old to **40 years** old

Gender

Female

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator

Sample size

Target sample size: **30**

Randomization (investigator's opinion)

Randomized

Randomization description

Method: Simple randomization Unit: Individual Tool:
Random numbers table

Blinding (investigator's opinion)

Double blinded

Blinding description

All participants in this project and the clinical caregiver who is responsible for getting medication to the participants and the physician (researcher) who collects the data, are blind to the type of intervention provided to each participant.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee**

Name of ethics committee

Ethics committee on Biomedical Research of Shahed University

Street address

Shahed University, Persian Gulf Highway (Tehran - Qom), Tehran

City

Tehran

Province

Tehran

Postal code

3319118651

Approval date

2018-12-24, 1397/10/03

Ethics committee reference number

IR.SHAHED.REC.1397.092

Health conditions studied**1****Description of health condition studied**

Polycystic ovarian syndrome

ICD-10 code

E28.2

ICD-10 code description

Polycystic ovarian syndrome

Primary outcomes**1****Description**

Presence of ovarian cysts

Timepoint

Before Intervention and seven days after Intervention

Method of measurement

Sonography

2**Description**

Occurrence of menstrual bleeding

Timepoint

4 and 8 weeks after the beginning of treatment

Method of measurement

asking

3**Description**

Hirsutism

Timepoint

Before Intervention and seven days after Intervention

Method of measurement

Ferriman-Gallwey scale

Secondary outcomes**1****Description**

Body mass index

Timepoint

Before Intervention and seven days after Intervention

Method of measurement

Meter and scale

2

Description

Total Testosterone

Timepoint

Before Intervention and seven days after Intervention

Method of measurement

CLIA laboratory method

3

Description

Free Testosterone

Timepoint

Before Intervention and seven days after Intervention

Method of measurement

ELIZA laboratory method

Intervention groups

1

Description

Case group: This group will be treated with Ferual Assafoetida (1 gram daily) for three weeks and discontinue the consumption for one week. Thereafter, patients will use the drugs for an extra three weeks.

Category

Treatment - Drugs

2

Description

Control group: This group will be treated with LD tablet with formulation of 0.03 mg Ethinyl Estradiol and 0.3 mg Norgestrel or 0.15 mg Levonorgestrel for three weeks and discontinue the consumption for one week. Thereafter, patients will use the drugs for an extra three weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Mostafa Komeini hospital

Full name of responsible person

DR. Ahia Garshasbi

Street address

Italia Ave., Felestin Ave.

City

Tehran

Province

Tehran

Postal code

3319118651

Phone

+98 21 8896 6131

Email

Dr.garshasbi@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shahed University

Full name of responsible person

Dr. Zahra Kiasalari

Street address

Shahed university, Persian Gulf Highway (Tehran - Qom)

City

Tehran

Province

Tehran

Postal code

3319118651

Phone

+98 21 5121 5106

Email

info@shahed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahed University

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Shahed University

Full name of responsible person

Najmeh Dehparvar

Position

Persian Medicine resident

Latest degree

Medical doctor

Other areas of specialty/work

Traditional Medicine

Street address

No. 26, Alley 2, Razavi Boulevard, Jihad Square, Bajak

City

Qom

Province

Ghous

Postal code

3713663547

Phone

+98 25 3770 1938

Email

n.dehparvar@shahed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahed University

Full name of responsible person

Najmeh Dehparvar

Position

Persian Medicine resident

Latest degree

Medical doctor

Other areas of specialty/work

Traditional Medicine

Street address

No. 26, Alley 2, Razavi Boulevard, Jihad Square, Bajak

City

Qom

Province

Ghous

Postal code

3713663547

Phone

+98 25 3770 1938

Email

dehparvar.1406@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Shahed University

Full name of responsible person

Najme Dehparvar

Position

Persian medicine resident

Latest degree

Medical doctor

Other areas of specialty/work

Traditional Medicine

Street address

No. 26, Alley 2, Razavi Boulevard, Jihad Square, Bajak,

City

Qom

Province

Ghous

Postal code

3713663547

Phone

+98 25 3770 1938

Email

dehparvar.mah@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

The information about the main outcome will be shared.

When the data will become available and for how long

The access period begins 6 months after publishing of results.

To whom data/document is available

It will be accessible to everyone.

Under which criteria data/document could be used

For scientific works with observing the principles of research ethics

From where data/document is obtainable

Najme Dehparvar, Mobile number: 00989122530421, Email: dehparvar.mah@gmail.com, Address: No. 26, Alley 2, Razavi Boulevard, Jihad Square, Qom

What processes are involved for a request to access data/document

Upon confirmation of the scientific identity of the Iranian questioner, he or she will be provided as soon as possible.

Comments